RQ Bio, a biotech startup, has secured $115 million in financing to advance its novel antibody designed to prevent influenza. The company claims its drug is “differentiated” from existing options, potentially offering durable protection against a broad range of flu strains.
The antibody targets conserved regions of the flu virus, which could make it effective across seasons and against emerging variants. Preclinical data suggest the therapy may provide long-lasting immunity, reducing the need for annual shots. Specific efficacy rates and trial data have not yet been disclosed.
The startup plans to use the funds to push the antibody into clinical testing. RQ Bio has not specified a regulatory pathway or timeline for filing with the FDA, though the focus on a preventive treatment positions it for potential fast-track designation. No PDUFA date has been set.
The $115 million round underscores growing investor appetite for alternatives to vaccines, especially after the COVID-19 pandemic highlighted gaps in pandemic preparedness. If successful, RQ Bio could challenge a market dominated by annual flu shots and seasonal antiviral treatments.
Skeptics note that past attempts at universal flu antibodies have struggled in human trials, often failing to match the breadth or durability seen in animal models. RQ Bio has yet to release peer-reviewed clinical data, making it difficult to assess its true potential.